Tuberculosis Trial Launched

The TB Alliance will test a new combination of drugs to combat normal and multi-drug-resistant tuberculosis.

Mar 20, 2012
Hannah Waters

WIKIMEDIA COMMONS, DVORTYGIRL

The TB Alliance is continuing its charge to develop a new drug regimen for people with tuberculosis, jumping regulatory hurdles to test several new combinations of drugs. Yesterday, the non-profit organization announced that they would begin a second clinical trial to test a new drug combination that can be taken for less time and, hopefully, work more effectively against the disease.

Currently, tuberculosis patients are prescribed a handful of antibiotics to be taken every day for 6 months. And if they develop a multi-drug-resistant form of tuberculosis, they will receive daily injections for 6 months, followed by 18 months of pill-popping.

In September 2010, the TB Alliance launched the first new phase II trial for new tuberculosis medicines in 50 years, testing a three-drug regimen: the experimental drug PA-824 with antibiotics moxifloxacin, and pyrazinamide. The first trial, completed in September 2011, only measured the drug’s safety and efficacy for 2 weeks.

The new trial will test the same drugs, but instead will last for 2 months, enroll around 250 people, and take place at 8 sites around Africa and South America.

The TB Alliance hopes that, with this drug combination, treatment time will be cut to 4 months, patients will take fewer pills, and costs will be lower.